News & Media
Main Menu
Presentations
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
All PRESENTATIONS
- All PRESENTATIONS
- AZP-3813
- Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)
KOL Event on Eneboparatide: A PTHR1 Agonist for Hypoparathyroidism
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide Development Update. ENDO 2023 KOL Event Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Treatment of Chronic Hypoparathyroidism with Eneboparatide (AZP-3601), a Novel PTH 1 Receptor Agonist: Results from a Phase 2 trial. ENDO 2023 Presentation.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Eneboparatide, a novel PTH1 receptor agonist, induces rapid reduction and normalization of urinary calcium in hypoparathyroid patients. ENDO 2023 Poster.
Written by
Dan Hennings
Eneboparatide (AZP-3601)
Variations in Clinical Practice Patterns for Hypoparathyroidism. ENDO 2023 Poster.
Written by
Dan Hennings
Upcoming events
39th Congress of the French Society of Endocrinology
Date: October 4-7, 2023 (Marseilles, France)
BIO Japan 2023
Date: October 11-13, 2023 (Yokohama, Japan)
American Society for Bone and Mineral Research 2023 Annual Meeting (ASBMR)
Date: October 13-16, 2023 (Vancouver, Canada)
Acromegaly Awareness Day
Date: November 1, 2023
2023 International HypoPARAthyroidism Conference
Date: November 3-4, 2023 (Sterling, VA)
Social Updates
TWITTER